ReviewCell communication and signaling : CCS2025
Taming fatty liver: can taurine combat metabolic dysfunction in MASLD?
Review in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: mechanistic networks and translational implications: a review.Journal of endocrinological investigation · 2026Review
- m1A Epitranscriptomic Control of NUPR1 by YTHDF1 Exacerbates Metabolic Dysregulation in Nonalcoholic Fatty Liver Disease.Journal of clinical and translational hepatology · 2026Article
- Taurine attenuates lipid accumulation via the eCB-CB1 axis: evidence from adipose metabolomics in HFD-fed mice and 3D adipocyte spheroids.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction associated with steatotic liver disease (MASLD) is the most prevalent chronic liver disease globally, significantly impacting human health and imposing substantial socioeconomic burdens. Characterized by excessive lipid accumulation in the liver, MASLD can progress to non-alcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma (HCC). Despite extensive research, the molecular mechanisms underlying MASLD remain incompletely understood, and no effective pharmacological treatments have been approved. This review explores the potential mechanisms of MASLD pathogenesis, early diagnostic approaches, and the promising role of taurine in mitigating MASLD progression via the gut-liver axis. As research advances, taurine may offer a novel therapeutic avenue, presenting new possibilities for effective clinical interventions in MASLD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.